PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trialVivek Narayan, Naomi B. Haas|Nature Medicine|2022Cited by 491
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.G. R. Hudes, C McAleer, Carine Khater et al.|Journal of Clinical Oncology|1997Cited by 273